Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Michael Matson has given his Buy rating due to a combination of factors involving the recent draft recommendation changes by the USPSTF regarding cervical cancer screening. The updates suggest a modest shift towards more frequent use of high-risk HPV testing, but these changes are not expected to significantly impact Hologic's revenue. Matson believes that the worst-case scenario for Hologic was avoided, as the recommendation did not remove the use of cytology or co-testing completely.
Additionally, Matson anticipates that while there may be a gradual shift in the medical community towards primary hrHPV testing, this transition will be slow and manageable, minimizing any negative financial effects on Hologic. The company's Cytology & Perinatal sales have remained stable in recent years, providing confidence in Hologic's ability to maintain its financial performance despite evolving screening recommendations.
Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HOLX in relation to earlier this year.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Hologic (HOLX) Company Description:
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a broad portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection, for mammography and minimally invasive breast biopsy devices, breast biopsy site markers, and breast biopsy guidance systems. The Diagnostics segment comprises Aptima family of Assays, target capture/nucleic acid extraction techonolgy, transcription-mediated amplification technology, hybridization protection assay and dual kinetic assat technologies, instrumentation, and Invader Chemistry Platform. The Medical Aesthetics segment offers SculpSure; PicoSure, MedLite, and RevLite; and MonaLisa Touch. The GYN Surgical segment encompasses the NovaSure Endometrial Ablation System and the MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment covers the discovery and horizon X-ray bone densitometry system, an ultrasound-based osteoporosis assessment product, and Fluoroscan mini C-arm imaging products. The company was founded by S. David Ellenbogen and Jay A. Stein in 1986 and is headquartered in Marlborough, MA.